Jukka Kemppainen

University of Turku

Papers

1

Total Citations

6

H-Index

1

About

Jukka Kemppainen is a leading figure in oncological imaging, with a primary focus on prostate cancer diagnostics. His research centers on the development and clinical validation of advanced molecular imaging techniques, particularly using prostate-specific membrane antigen (PSMA) PET/CT. Kemppainen’s major contribution lies in rigorously comparing novel imaging modalities against the gold standard of histopathology. In his highly cited prospective study, he demonstrated the superior accuracy of 18F-PSMA-1007 PET/CT over whole-body MRI for intraprostatic tumor detection and T-staging in high-risk prostate cancer. This work, which has already garnered significant attention, directly informs clinical decision-making by clarifying the strengths of each modality. Beyond diagnostic performance, his research uniquely correlates in vivo PSMA uptake with immunohistochemical expression, bridging imaging and pathology. With a citation count reflecting the immediate relevance of his findings, Kemppainen’s work is pivotal for urologists, radiologists, and nuclear medicine specialists seeking to optimize staging and treatment planning for prostate cancer patients.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer
6 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: University of Turku

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago